Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both eyes.~Exclusion Criteria:~* Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or any of the ingredients in the study drug.~* Subjects with known contraindications to NO treatment.~* Subjects who are unable to discontinue contact lens use at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.~* Subjects who are unable to discontinue the use of all topical ophthalmic medications, including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.~* Subjects with any condition that prevents reliable applanation tonometry in either eye.~* Subjects with glaucoma in either eye.~* Subjects with any condition that prevents clear visualization of the fundus.~* Subjects who are monocular.~* Subjects with aphakia in either eye.~* Subjects with an active corneal disease in either eye.~* Subjects with severe dry eye in either eye.~* Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects with any intraocular infection or inflammation within 3 months (90 days) prior to Visit 1 (Screening).~* Subjects with a history of ocular laser surgery within the 3 months (90 days) prior to Visit 1 (Screening).~* Subjects with a history of incisional ocular surgery or severe trauma.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Latanoprostene Bunod (Type: EXPERIMENTAL): Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).